Information Provided By: 
Fly News Breaks for June 27, 2017
OSUR
Jun 27, 2017 | 11:31 EDT
Canaccord analyst Mark Massaro said OraSure's agreement with the Bill & Melinda Gates Foundation will effectively subsidize the cost of the company's HIV self test, which can add millions of revenue beginning in 2018, with some partial lift in 2017. The analyst, who views OraSure as having " multiple shots on goal" in addition to the HIV test, keeps a Buy rating on the stock and raised his price target to $18 from $15.
News For OSUR From the Last 2 Days
There are no results for your query OSUR
